Pesquisar
Transcode Therapeutics Inc
RNAZAdicionar à lista de desejos
6.210USD
+0.970+18.51%
Fechamento 06/30, 16:00（ET）Cotações atrasadas em 15 min
5.90MValor de mercado
PerdaP/L TTM
Mais detalhes de Transcode Therapeutics Inc Empresa
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Informações de Transcode Therapeutics Inc
Código da empresaRNAZ
Nome da EmpresaTranscode Therapeutics Inc
Data de listagemApr 28, 2021
CEOCalais (Philippe P)
Número de funcionários7
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 28
Endereço6 Liberty Square
CidadeBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02109
Telefone18573016857
Sitehttps://www.transcodetherapeutics.com/
Código da empresaRNAZ
Data de listagemApr 28, 2021
CEOCalais (Philippe P)
Executivos da empresa Transcode Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Transcode Therapeutics Inc?
Os cinco principais acionistas de Transcode Therapeutics Inc são: Mr. Thomas A. (Tom) Fitzgerald
Quantas instituições possuem ações da Transcode Therapeutics Inc (RNAZ)?
Em 2026Q1, 37 instituições possuíam ações da Transcode Therapeutics Inc, com valor de mercado aproximado de 77.85K, representando 8.49% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -42306.00.